Press release | 24th May 2010
IDBS hosts Translational and Biomarker Research Symposium
Features State-of-the-Art Commercial and Academic Deployments
Guildford, UK, and Burlington, Mass., May 24, 2010 – IDBS, the leading worldwide provider of research data management and analytics solutions to R&D organizations, today announced that it will hold its bi-annual US Translational and Biomarker Research Symposium on Thursday, June 3 in Boston, Mass.
The event will focus on secure and sophisticated data management for biomarker and translational research and will highlight examples of how such solutions enable pharmaceutical and medical institutions to better capture and integrate clinical, image, and genomic data and manage their scientific knowledge and intellectual property (IP). The symposium provides a forum for members of the pharmaceutical, biotechnology and medical research communities to network, hear real-world case studies, and share ideas on how to change the pace of translational and biomarker research.
The event will feature sessions from:
- Dr. John Quackenbush, Professor of Computational Biology and Bioinformatics, Dana-Farber Cancer Institute
- Dr. Jonathan Sheldon, Director of Translational Medicine, IDBS
- Daniel Ingber, Sr. Manager Information Systems Research, MedImmune
- Dr. Hakon Hakonarson, Director of the Center for Applied Genomics, Children’s Hospital of Philadelphia
- Kris Joshi, PhD, VP, Healthcare Strategy and Business Development, Health Sciences Global Business Unit, Oracle
- Mick Correll, Associate Director of the Center for Cancer Computational Biology, Dana-Farber Cancer Institute
“IDBS provides unique value to our customers by combining our extensive domain knowledge with innovative technology and the ability to deliver these solutions to the market. We are pleased to be working closely with the recognized pioneers in the field of translational and biomarker research,” said Neil Kipling, founder and CEO of IDBS. “Our global series of symposia bring together an influential group of organizations who are deeply dedicated to accelerating therapeutic research, enabling them to share their experiences and providing a forum in which to develop new ideas.”
IDBS is a unique, global supplier of innovative data management and analytics solutions, which increase efficiency, reduce costs and improve business and scientific productivity of R&D organizations worldwide. Organizations such as Pfizer, GSK, Celera, MedImmune, Dana-Farber, and Roche employ IDBS solutions as an integral part of their strategy to address the increasing pressures placed upon them by the need for the secure, compliant capture, integration and analysis of complex research data. IDBS is clearly differentiated from other software providers by its unique combination of deep domain knowledge and its ability to rapidly provide integrated business process and robust data analytics solutions along the entire R&D value chain. IDBS solutions secure organizations’ valuable R&D data assets and enable rapid decision-making through effective integration and analysis. They also support the protection of Intellectual Property (IP) and the requirements for data quality demanded under Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) standards.
IDBS is a private company, founded in 1989 and headquartered in Guildford, UK. IDBS has worldwide consulting and support presence, with U.S. offices in California, New Jersey and Massachusetts, the EU, Australia and China.